Literature DB >> 25768255

MyD-88 L265P mutations are present in some cases of vitreoretinal lymphoma.

Jose S Pulido1, Diva R Salomao, Lori A Frederick, David S Viswanatha.   

Abstract

PURPOSE: To determine whether Myd88 L265P mutations occur in diffuse large B-cell vitreoretinal lymphomas.
METHODS: The formalin-fixed paraffin-embedded cells from three patients with classic clinical findings of vitreoretinal lymphoma that also had histologic confirmation were evaluated using a validated amplification-refractory mutation system polymerase chain reaction to determine the presence of the mutation.
RESULTS: The 74 ± 2 base pair product seen from the mutated Myd-88 protein was noted in 2 of the 3 cases.
CONCLUSION: Myd-88 L265P constitutive activating mutations are present in at least some cases of the diffuse large B-cell lymphoma form of vitreoretinal lymphoma. Further studies on the incidence of this mutation in retinal lymphomas are warranted.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25768255     DOI： 10.1097/IAE.0000000000000589

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


  8 in total

1.  Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.

Authors:  Andi K Cani; Daniel H Hovelson; Hakan Demirci; Mark W Johnson; Scott A Tomlins; Rajesh C Rao
Journal:  Oncotarget       Date:  2017-01-31

Review 2.  Primary vitreoretinal lymphoma: prevalence, impact, and management challenges.

Authors:  Ramesh Venkatesh; Bharathi Bavaharan; Padmamalini Mahendradas; Naresh Kumar Yadav
Journal:  Clin Ophthalmol       Date:  2019-02-14

3.  The use of anterior segment optical coherence tomography (ASOCT) in demonstrating recurrence of vitreoretinal lymphoma (VRL) in the anterior vitreous.

Authors:  Vlad Diaconita; Heba Rihani; Virginia Mares; Marcio B Nehemy; Sophie J Bakri; Jose S Pulido
Journal:  Int J Retina Vitreous       Date:  2019-08-20

4.  Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma.

Authors:  Laura Fogliatto; Kamila Castro Grokoski; Yuri Machado Strey; Tito Vanelli; Christina Garcia da Silva Fraga; Marines Bizarro Barra; Fernanda Correa Pinto; Israel Bendit; Claúdia Giuliano Bica
Journal:  Hematol Transfus Cell Ther       Date:  2018-10-24

5.  Diagnosing Vitreoretinal Lymphomas-An Analysis of the Sensitivity of Existing Tools.

Authors:  Anahita Sehgal; Jose S Pulido; Arman Mashayekhi; Tatyana Milman; Gabor Gy Deák
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

Review 6.  Update in Molecular Testing for Intraocular Lymphoma.

Authors:  Michael J Heiferman; Michael D Yu; Prithvi Mruthyunjaya
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

Review 7.  The diagnosis and treatment of primary vitreoretinal lymphoma: a review.

Authors:  Jose S Pulido; Patrick B Johnston; Grzegorz S Nowakowski; Alessia Castellino; Harish Raja
Journal:  Int J Retina Vitreous       Date:  2018-05-07

8.  MYD88 L265P mutation in intraocular lymphoma: A potential diagnostic marker.

Authors:  Sandhya Narasimhan; Mayur Joshi; Sowmya Parameswaran; Pukhraj Rishi; Vikas Khetan; Suganeswari Ganesan; Jyotirmay Biswas; Natarajan Sundaram; Janani Sreenivasan; Sonali Verma; Vanitha Krishnamurthy; Krishnakumar Subramanian
Journal:  Indian J Ophthalmol       Date:  2020-10       Impact factor: 1.848
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.